Navigation Links
Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval
Date:8/5/2009

SEATTLE, Aug. 6 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) today reported recent achievements and financial results for the second quarter and six months ended June 30, 2009.

"The second quarter of 2009 was a transforming quarter for the Company as we reported, in a peer reviewed setting, pixantrone phase III data at the American Society of Clinical Oncology Annual Meeting and completed the submission of the pixantrone New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA)," said James A. Bianco, M.D., CEO of Cell Therapeutics. "On the financial front, we continue to reduce and control our operating expenses, eliminated 44.5% of our outstanding debt through exchange offers completed in June 2009, and raised significant capital to continue to advance pixantrone to market."

Recent Highlights

  • Completed the submission of the pixantrone NDA to the FDA to treat relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL). CTI requested priority review of the pixantrone NDA which, if granted, could lead to an approval decision from the FDA in the fourth quarter of 2009.
  • Reduced outstanding debt by $52.9 million, representing 44.5% of outstanding debt, through exchange offers completed in June 2009, resulting in an estimated savings in future annual interest expense of approximately $3.3 million.
  • Added to the Russell 3000(R), Russell 2000(R) and Russell Global(R) Indexes.
  • Raised $43.8 million in gross proceeds in connection with financing transactions in the second quarter of 2009, and an additional $41.7 million in proceeds, net of underwriting discount, in connection with an underwritten offering of common stock and warrants in July 2009.

For the quarter ended June 30, 2009, total net operating expenses decreased approximat
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  United Therapeutics ... that Medtronic, Inc. (NYSE: MDT ) ... U.S. Food and Drug Administration (FDA) for the ... drug infusion system (including a newly developed catheter) ... (treprostinil) Injection delivered intravenously to patients with pulmonary ...
(Date:12/24/2014)... NEW YORK , Dec. 24, 2014 ... biopharmaceutical company advancing patient care in critical areas, announced ... shares of common stock, and warrants to purchase up ... an offering price of $4.00 per share and $.01 ... price of $5.00, are exercisable immediately, and expire 5 ...
(Date:12/24/2014)... , Dec. 24, 2014  Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that the Company closed ... Oracle Investment Management, Jack W. Schuler , ... proceeds were $10.5 million, before offering expenses.  The ... general corporate purposes. Under the terms ...
(Date:12/24/2014)... --  BioLife Solutions , Inc. (NASDAQ: BLFS ... clinical grade hypothermic storage and cryopreservation ... for cells and tissues  ("BioLife" or the "Company"), ... Meeting of Stockholders on May 4, 2015 (the "Annual ... Annual Meeting represents a change of more than 30 ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3BioLife Solutions Sets Date for Annual Meeting of Stockholders 2
... Baxter Healthcare Corporation,today announced its V-Link ... first needleless intravenous (IV) connector to,contain an ... in the,United States and Canada. V-Link with ... 99.9 percent or more of specific common ...
... discussed during Omnicell,educational, programs April 15 at ... The Mid-America Club in Chicago, MOUNTAIN ... Inc. (Nasdaq: OMCL ), a leading provider,of ... in,healthcare facilities, and Rice Memorial Hospital today announced ...
... Collins, M.D., Ph.D. a,physician-geneticist and leader of ... of the inaugural Inamori Ethics Prize from ... at Case Western Reserve,University., (Photo: ... Prize honors outstanding international ethical,leaders. It is ...
Cached Biology Technology:Baxter's V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals 2Baxter's V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals 3Baxter's V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals 4Rice Memorial Hospital Implements SinglePointe(TM) Automated Patient-Specific Management Solution From Omnicell 2Rice Memorial Hospital Implements SinglePointe(TM) Automated Patient-Specific Management Solution From Omnicell 3Leading Geneticist Francis Collins Named First Recipient of the Inamori Ethics Prize at Case Western Reserve University 2Leading Geneticist Francis Collins Named First Recipient of the Inamori Ethics Prize at Case Western Reserve University 3Leading Geneticist Francis Collins Named First Recipient of the Inamori Ethics Prize at Case Western Reserve University 4
(Date:12/24/2014)... 2014  Since its launch in December 2014, the ... to eliminate the pain of trying to remember their ... their own biometrics fused to their smartphones. To assist ... Hoyos Labs , the company that created 1U ... is offering the app for free. 1U ...
(Date:12/22/2014)... SHELTON, Conn. , Dec. 22, 2014  NXT-ID, ... or the "Company"), a biometric authentication company focused on ... famous pickpocket, entertainer and security consultant, Apollo Robbins ... Wocket™ biometric smart wallet.  Apollo ... 6th and 7 th , 2015, demonstrating some of ...
(Date:12/22/2014)... 2014 Research and Markets ... of the "The Global Watermarking and ... http://photos.prnewswire.com/prnh/20130307/600769 ... of the global digital media watermarking and ... monitor piracy by securely and invisibly embedding ...
Breaking Biology News(10 mins):1U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4The Global Watermarking and Fingerprinting Markets 2
... which set out to investigate DNA methylation in the human ... health, has now mapped the link in detail across the ... a field that is still in its scientific infancy and ... even 18 months ago. Researcher Roger Foo explains: ...
... appears to make eye tumors less likely to grow if ... researchers at Washington University School of Medicine in St. Louis. ... Clinical Cancer Research . Uveal melanoma, the second most ... or metastasize, from the eye to other organs, especially the ...
... world that her computer model of a key brain ... potential relevance to Parkinson,s disease, Stephanie Jones sought to ... now close collaborators, but when they first started talking ... Jones was plain wrong, if not a bit nuts. ...
Cached Biology News:Environment and diet leave their prints on the heart 2Drug may slow spread of deadly eye cancer 2Drug may slow spread of deadly eye cancer 3Drug may slow spread of deadly eye cancer 4Drug may slow spread of deadly eye cancer 5New study to test unusual hypothesis on beta brainwaves 2New study to test unusual hypothesis on beta brainwaves 3New study to test unusual hypothesis on beta brainwaves 4
... BAC (100+kb), fosmid (40kb), and large plasmid ... any othe BAC vector. On command 20-50 ... easy recombinant DNA purification. Available with blue-white ... vectors for the highest insert stability. Kits ...
Trop-2 Purified Anti-Human clone 162-46, Isotype Mouse IgG 1 , 100 µg Consult technical datasheet for details....
... Error-free cloning of BAC (100+kb), fosmid (40kb), ... insert stability than any othe BAC vector. ... high yields and easy recombinant DNA purification. ... transcription-free (pSMART VC) vectors for the highest ...
... to Sf-900 II SFM.Sf21 ... from Spodoptera frugiperda (Fall ... (1). The Sf21 cells ... suspension culture in Sf-900 ...
Biology Products: